Share-based Payment Arrangement, Expense of Deciphera Pharmaceuticals, Inc. from 31 Dec 2015 to 31 Mar 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Deciphera Pharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2015 to 31 Mar 2024.
  • Deciphera Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2024 was $10,174,000, a 19% decline year-over-year.
  • Deciphera Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Mar 2024 was $48,263,000, a 3.8% decline year-over-year.
  • Deciphera Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $50,603,000, a 2.6% decline from 2022.
  • Deciphera Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $51,942,000, a 13% increase from 2021.
  • Deciphera Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $46,078,000, a 24% increase from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Deciphera Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $48,263,000 $10,174,000 -$2,340,000 -19% 01 Jan 2024 31 Mar 2024 10-Q 10 May 2024 2024 Q1
Q4 2023 $50,603,000 $14,073,000 +$1,760,000 +14% 01 Oct 2023 31 Dec 2023 10-K 07 Feb 2024 2023 FY
Q3 2023 $48,843,000 $11,160,000 -$1,213,000 -9.8% 01 Jul 2023 30 Sep 2023 10-Q 30 Oct 2023 2023 Q3
Q2 2023 $50,056,000 $12,856,000 -$132,000 -1% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2023 2023 Q2
Q1 2023 $50,188,000 $12,514,000 -$1,754,000 -12% 01 Jan 2023 31 Mar 2023 10-Q 10 May 2024 2024 Q1
Q4 2022 $51,942,000 $12,313,000 +$1,519,000 +14% 01 Oct 2022 31 Dec 2022 10-K 07 Feb 2024 2023 FY
Q3 2022 $50,423,000 $12,373,000 +$579,000 +4.9% 01 Jul 2022 30 Sep 2022 10-Q 30 Oct 2023 2023 Q3
Q2 2022 $49,844,000 $12,988,000 +$617,000 +5% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $49,227,000 $14,268,000 +$3,149,000 +28% 01 Jan 2022 31 Mar 2022 10-Q 03 May 2023 2023 Q1
Q4 2021 $46,078,000 $10,794,000 +$1,088,000 +11% 01 Oct 2021 31 Dec 2021 10-K 07 Feb 2024 2023 FY
Q3 2021 $44,990,000 $11,794,000 +$1,966,000 +20% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $43,024,000 $12,371,000 +$1,762,000 +17% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $41,262,000 $11,119,000 +$4,125,000 +59% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022 2022 Q1
Q4 2020 $37,137,000 $9,706,000 +$4,361,000 +82% 01 Oct 2020 31 Dec 2020 10-K 07 Feb 2023 2022 FY
Q3 2020 $32,776,000 $9,828,000 +$5,099,000 +108% 01 Jul 2020 30 Sep 2020 10-Q 02 Nov 2021 2021 Q3
Q2 2020 $27,677,000 $10,609,000 +$6,502,000 +158% 01 Apr 2020 30 Jun 2020 10-Q 03 Aug 2021 2021 Q2
Q1 2020 $21,175,000 $6,994,000 +$765,000 +12% 01 Jan 2020 31 Mar 2020 10-Q 04 May 2021 2021 Q1
Q4 2019 $20,410,000 $5,345,000 +$2,540,000 +91% 01 Oct 2019 31 Dec 2019 10-K 08 Feb 2022 2021 FY
Q3 2019 $17,870,000 $4,729,000 +$2,115,000 +81% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $15,755,000 $4,107,000 +$1,875,000 +84% 01 Apr 2019 30 Jun 2019 10-Q 04 Aug 2020 2020 Q2
Q1 2019 $13,880,000 $6,229,000 +$4,192,000 +206% 01 Jan 2019 31 Mar 2019 10-Q 05 May 2020 2020 Q1
Q4 2018 $9,688,000 $2,805,000 -$39,000 -1.4% 01 Oct 2018 31 Dec 2018 10-K 09 Feb 2021 2020 FY
Q3 2018 $9,727,000 $2,614,000 +$1,602,000 +158% 01 Jul 2018 30 Sep 2018 10-Q 04 Nov 2019 2019 Q3
Q2 2018 $8,125,000 $2,232,000 +$1,638,000 +276% 01 Apr 2018 30 Jun 2018 10-Q 02 Aug 2019 2019 Q2
Q1 2018 $6,487,000 $2,037,000 +$1,621,000 +390% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $4,866,000 $2,844,000 01 Oct 2017 31 Dec 2017 10-K 09 Mar 2020 2019 FY
Q3 2017 $1,012,000 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $594,000 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018 2018 Q2
Q1 2017 $416,000 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018 2018 Q1

Deciphera Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $50,603,000 -$1,339,000 -2.6% 01 Jan 2023 31 Dec 2023 10-K 07 Feb 2024 2023 FY
2022 $51,942,000 +$5,864,000 +13% 01 Jan 2022 31 Dec 2022 10-K 07 Feb 2024 2023 FY
2021 $46,078,000 +$8,941,000 +24% 01 Jan 2021 31 Dec 2021 10-K 07 Feb 2024 2023 FY
2020 $37,137,000 +$16,727,000 +82% 01 Jan 2020 31 Dec 2020 10-K 07 Feb 2023 2022 FY
2019 $20,410,000 +$10,722,000 +111% 01 Jan 2019 31 Dec 2019 10-K 08 Feb 2022 2021 FY
2018 $9,688,000 +$4,822,000 +99% 01 Jan 2018 31 Dec 2018 10-K 09 Feb 2021 2020 FY
2017 $4,866,000 +$3,379,000 +227% 01 Jan 2017 31 Dec 2017 10-K 09 Mar 2020 2019 FY
2016 $1,487,000 -$1,070,000 -42% 01 Jan 2016 31 Dec 2016 10-K 14 Mar 2019 2018 FY
2015 $2,557,000 01 Jan 2015 31 Dec 2015 10-K 28 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.